Adiso Therapeutics develops medications to treat inflammatory diseases.
Adiso Therapeutics has raised $60.0M in total funding. The most recent round was Series A. The last funding was announced in March 2022.
Adiso Therapeutics's investors include Morningside.
Adiso Therapeutics is headquartered in Concord, United States.
Adiso Therapeutics develops medications to treat inflammatory diseases.
Adiso Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Adiso Therapeutics — Funding & Investors." VCBacked, March 10, 2022, https://www.vcbacked.co/company/adiso-therapeutics. Accessed September 30, 2026.
VCBacked. (2022). Adiso Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/adiso-therapeutics
{{cite web |title=Adiso Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/adiso-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated